Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.54 |
| ▸ | PPARA | Q07869 | 20/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619881 | 0.92 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL3743468 | 0.92 | PPARG (0.55) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL29365673 | 0.91 | PPARG (0.64) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL2642937 | 0.91 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL7620874 | 0.91 | PPARG (0.55) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL22607966 | 0.91 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL13524846 | 0.88 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3745188 | 0.88 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3730093 | 0.87 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL5049259 | 0.86 | PPARG (0.66) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010008902-A1 | Method for producing thiazolidinediones, and new thiazolidinediones | KUHNLE HANS-FRIEDER (DE) | 2001-07-19 | — | — | US | claimed |
| US-6441185-B2 | REDUCTION OF AN UNSATURATED THIAZOLIDINE-2,4-DIONE DERIVATIVE WITH METALLIC ALUMINUM IN A PROTIC SOLVENT; PURITY; ANTIDIABETIC AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2002-08-27 | — | — | US | disclosed |
| US-20010008902-A1 | Method for producing thiazolidinediones, and new thiazolidinediones | KUHNLE HANS-FRIEDER (DE) | 2001-07-19 | — | — | US | disclosed |
| US-6258832-B1 | REDUCTION OF COMPOUNDS WITH ALUMINUM IN APROTIC SOLVENT | ROCHE DIAGNOSTICS GMBH (DE) | 2001-07-10 | — | — | US | disclosed |
| EP-0970077-A1 | IMPROVED METHOD FOR PRODUCING THIAZOLIDINEDIONES, AND NEW THIAZOLIDINEDIONES | Roche Diagnostics GmbH (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998042704-A1 | IMPROVED METHOD FOR PRODUCING THIAZOLIDINEDIONES, AND NEW THIAZOLIDINEDIONES | ROCHE DIAGNOSTICS GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008902-A1 | Method for producing thiazolidinediones, and new thiazolidinediones | NR4A1, NR2C2, NR5A2 | PPARG 39/4885PPARA 30/4885PPARD 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.